Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why?.
Research article published in European heart journal (2013)
Abstract
Decision making with regard to thromboprophylaxis should be based upon the absolute risks of stroke/thromboembolism and bleeding and the net clinical benefit for a given patient. As a consequence, a crucial part of atrial fibrillation (AF) management requires the appropriate use of thromboprophylaxis, and the assessment of stroke as well as bleeding risk can help inform management decisions by clinicians. The objective of this review article is to provide an overview of stroke and bleeding risk assessment in AF. There would be particular emphasis on when, how, and why to use these risk stratification schemes, with a specific focus on the CHADS2 [congestive heart failure, hypertension, age, diabetes, stroke (doubled)], CHA2DS2-VASc [congestive heart failure or left ventricular dysfunction, hypertension, age ≥ 75 (doubled), diabetes, stroke (doubled)-vascular disease, age 65-74 and sex category (female)], and HAS-BLED [hypertension (i.e. uncontrolled blood pressure), abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR (if on warfarin), elderly (e.g. age >65, frail condition), drugs (e.g. aspirin, NSAIDs)/alcohol concomitantly] risk scores.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why?.
Por qué esto importa para la hirudoterapia
Este artículo de revisión proporciona una visión general de la evaluación del riesgo de ictus y hemorragia en la fibrilación auricular, centrándose en los esquemas de estratificación de riesgo CHADS2, CHA2DS2-VASc y HAS-BLED para guiar las decisiones de tromboprofilaxis. El resumen aborda los marcos de toma de decisiones sobre anticoagulantes, pero no hace referencia alguna a las sanguijuelas, la hirudoterapia, la hirudina ni a ninguna sustancia derivada de la sanguijuela. No existe una relevancia defendible relacionada con las sanguijuelas; el contenido pertenece por completo al ámbito de la estratificación de riesgo de anticoagulantes orales para pacientes cardíacos.
Citación
Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why?.
Lip · European heart journal, 2013
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026